Imipenem/Cilastatine Hikma

Imipenem/cilastatin, the active ingredient in Imipenem/Cilastatin Hikma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats serious bacterial infections in hospitalized patients, including complicated intra‑abdominal, urinary tract, skin and soft‑tissue, lower respiratory tract infections, and febrile neutropenia.

GNH USA supplies Imipenem/Cilastatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products globally.

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used to treat severe bacterial infections in various organ systems.

- Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens, helping resolve peritonitis and intra‑abdominal sepsis. - Complicated urinary tract infections: eliminates resistant Gram‑negative organisms, facilitating cure of pyelonephritis and complicated cystitis. - Complicated skin and soft‑tissue infections: provides coverage against MRSA‑like organisms and polymicrobial flora in deep tissue infections. - Community‑acquired and hospital‑acquired lower respiratory tract infections: treats pneumonia caused by resistant Streptococcus pneumoniae, Pseudomonas aeruginosa and other pathogens. - Febrile neutropenia: offers rapid bactericidal activity in immunocompromised patients with fever of unknown origin.

Imipenem/cilastatin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Rash: erythematous skin eruption.

Serious or Rare Side Effects: - Seizures: increased risk, especially with renal impairment. - Anaphylaxis: severe allergic reaction with hives and airway swelling. - Clostridioides difficile‑associated diarrhea: potentially severe colitis.

Before initiating imipenem/cilastatin therapy, clinicians should consider several safety precautions to minimize risks. - Renal function assessment: evaluate creatinine clearance and adjust dose in impairment. - Monitor for seizures: observe patients with CNS disorders or electrolyte abnormalities. - Hypersensitivity screening: avoid use in individuals with known carbapenem allergy. - Concomitant valproic acid: discontinue or replace, as imipenem reduces valproate levels. - Use with caution in pregnant or breastfeeding patients: benefits must outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces plasma valproate concentrations, risking loss of seizure control. - Probenecid: may increase imipenem levels, heightening neurotoxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): additive nephrotoxic potential, monitor renal function. - Aminoglycosides (e.g., gentamicin): combined nephrotoxicity, adjust dosing as needed. - Warfarin: possible alteration of INR, check coagulation parameters regularly.